{"id":701656,"date":"2024-06-06T07:30:02","date_gmt":"2024-06-06T07:30:02","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=701656"},"modified":"2024-06-06T07:30:02","modified_gmt":"2024-06-06T07:30:02","slug":"seborrhoeic-dermatitis-market-to-witness-upsurge-in-growth-during-the-forecast-period-arcutis-biotherapeutics-cutanea-life-sciences-dermbiont-astion-pharma-amorepacific-matrisys-bio","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/seborrhoeic-dermatitis-market-to-witness-upsurge-in-growth-during-the-forecast-period-arcutis-biotherapeutics-cutanea-life-sciences-dermbiont-astion-pharma-amorepacific-matrisys-bio_701656.html","title":{"rendered":"Seborrhoeic Dermatitis Market to Witness Upsurge in Growth During the Forecast Period | Arcutis Biotherapeutics, Cutanea Life Sciences, DermBiont, Astion Pharma, Amorepacific, MatriSys Bio"},"content":{"rendered":"
\n
\"Seborrhoeic<\/a><\/div>\n
\n
Seborrhoeic Dermatitis Market<\/div>\n<\/div>\n<\/div>\n
The Seborrhoeic Dermatitis Market is anticipated to grow in the coming years owing to the potential launch of the pipeline therapiee, the rise in healthcare spending across the world, and the rise in the number of cases of Seborrhoeic Dermatitis in the 7MM. Key players, such as Arcutis Biotherapeutics, Cutanea Life Sciences, and others, are involved in developing drugs for Seborrhoeic Dermatitis.<\/div>\n

DelveInsight’s “Seborrhoeic Dermatitis Market Insights, Epidemiology, and Market Forecast 2032<\/strong><\/a>” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Seborrhoeic Dermatitis market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).<\/p>\n

The Seborrhoeic Dermatitis market report covers emerging drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice\/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.<\/p>\n

Seborrhoeic Dermatitis Overview<\/strong><\/p>\n

Seborrheic dermatitis is a common, chronic skin condition characterized by scaly, itchy, and red patches on the skin. It’s often seen on the scalp, where it can cause dandruff, but it can also appear on other areas of the body where sebaceous (oil) glands are numerous, such as the face, ears, chest, and back. The condition is more prevalent in adults, but it can affect people of all ages, including infants, where it’s known as cradle cap.<\/p>\n

Seborrhoeic Dermatitis Market Key Facts<\/strong><\/p>\n

According to Clark et al. (2015), the prevalence of seborrheic dermatitis is 1% to 3% in the general population and 34% to 83% in immune-compromised persons. It has a bimodal distribution, with peaks at two to 12 months of age and in adolescence and early adulthood.<\/p>\n

As per Berl et al., the worldwide prevalence of seborrheic dermatitis is around 5%, but the prevalence of its non-inflammatory variant, dandruff, is probably closer to 50%.<\/p>\n

Incidence is 1–3% of the general adult population. Men are affected more frequently than women.<\/p>\n

As per the National Eczema Association, people of any age can develop seborrheic dermatitis, including infants; however, it is slightly more common in men than women.<\/p>\n

Seborrhoeic Dermatitis Market<\/strong><\/a><\/p>\n

The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted Seborrhoeic Dermatitis market size by analyzing the impact of current and emerging pipeline therapies. It also provides a thorough assessment of the market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.<\/p>\n

The report gives complete detail of the Seborrhoeic Dermatitis market trend for each marketed drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.<\/p>\n

Seborrhoeic Dermatitis Epidemiology Assessment<\/strong><\/p>\n

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pool, future trends, and views of key opinion leaders.<\/p>\n

The Report Covers the Seborrhoeic Dermatitis Epidemiology, Segmented as –<\/strong><\/p>\n

Total Prevalent Pool of Seborrheic dermatitis in the 7MM [2019–2032]<\/p>\n

Treated Prevalent Pool of Seborrheic dermatitis in the 7MM [2019–2032]<\/p>\n

Gender-specific Prevalent Pool of Seborrheic dermatitis in the 7MM [2019–2032]<\/p>\n

Diagnosed Prevalent Pool of Seborrheic dermatitis in the 7MM [2019–2032]<\/p>\n

Age-specific Prevalent Pool of Seborrheic dermatitis in the 7MM [2019–2032]<\/p>\n

Seborrhoeic Dermatitis Drugs Uptake and Pipeline Development Activities<\/strong><\/p>\n

The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Seborrhoeic Dermatitis market or expected to be launched during the study period. The analysis covers the Seborrhoeic Dermatitis market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.<\/p>\n

The report also covers the Seborrhoeic Dermatitis pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.<\/p>\n

Learn How the Seborrhoeic Dermatitis Market Will Evolve and Grow by 2032 @ https:\/\/www.delveinsight.com\/sample-request\/seborrhoeic-dermatitis-market<\/a><\/strong><\/p>\n

Seborrhoeic Dermatitis Therapeutics Analysis<\/strong><\/p>\n

Several major pharma and biotech giants are developing therapies for Seborrhoeic Dermatitis. Currently, Arcutis Biotherapeutics is leading the therapeutics market with its Seborrhoeic Dermatitis drug candidates in the mid to advanced stage of clinical development.<\/p>\n

Leading Companies in the Seborrhoeic Dermatitis Therapeutics Market Include:<\/strong><\/p>\n

Arcutis Biotherapeutics<\/p>\n

Cutanea Life Sciences<\/p>\n

DermBiont<\/p>\n

Astion Pharma A\/S<\/p>\n

Amorepacific<\/p>\n

MatriSys Bio<\/p>\n

Amorepacific<\/p>\n

And Many Others<\/p>\n

Seborrhoeic Dermatitis Emerging and Market Drugs Covered in the Report Include:<\/strong><\/p>\n

DBI-002: DermBiont<\/p>\n

MSB-7154: MatriSys Bio<\/p>\n

Omiganan (CLS002): Cutanea Life Sciences<\/p>\n

PAC 14028: Amorepacific<\/p>\n

Topical roflumilast foam (ARQ-154): Arcutis Biotherapeutics<\/p>\n

And Many More<\/p>\n

The pipeline for Seborrheic Dermatitis brings a positive ray of hope for potential treatment options in the market in the upcoming years. The current scenario also anticipates a positive shift in the market for a study period.<\/p>\n

The Report Covers the In-depth Assessment of the Emerging Drugs & Key Companies. Download the Sample Report to Learn More @ https:\/\/www.delveinsight.com\/sample-request\/seborrhoeic-dermatitis-market<\/a><\/strong><\/p>\n

Table of Contents<\/strong><\/p>\n

1. Key Insights<\/p>\n

2. Executive Summary<\/p>\n

3. Seborrhoeic Dermatitis Competitive Intelligence Analysis<\/p>\n

4. Seborrhoeic Dermatitis Market Overview at a Glance<\/p>\n

5. Seborrhoeic Dermatitis Disease Background and Overview<\/p>\n

6. Seborrhoeic Dermatitis Patient Journey<\/p>\n

7. Seborrhoeic Dermatitis Epidemiology and Patient Population (In the US, EU5, and Japan)<\/p>\n

8. Seborrhoeic Dermatitis Treatment Algorithm, Current Treatment, and Medical Practices<\/p>\n

9. Seborrhoeic Dermatitis Unmet Needs<\/p>\n

10. Key Endpoints of Seborrhoeic Dermatitis Treatment<\/p>\n

11. Seborrhoeic Dermatitis Marketed Products<\/p>\n

12. Seborrhoeic Dermatitis Emerging Drugs and Latest Therapeutic Advances<\/p>\n

13. Seborrhoeic Dermatitis Seven Major Market Analysis<\/p>\n

14. Attribute Analysis<\/p>\n

15. Seborrhoeic Dermatitis Market Outlook (In US, EU5, and Japan)<\/p>\n

16. Seborrhoeic Dermatitis Access and Reimbursement Overview<\/p>\n

17. KOL Views on the Seborrhoeic Dermatitis Market<\/p>\n

18. Seborrhoeic Dermatitis Market Drivers<\/p>\n

19. Seborrhoeic Dermatitis Market Barriers<\/p>\n

20. Appendix<\/p>\n

21. DelveInsight Capabilities<\/p>\n

22. Disclaimer<\/p>\n

Download the Sample PDF to Learn More About the Key Offerings of the Report @ https:\/\/www.delveinsight.com\/sample-request\/seborrhoeic-dermatitis-market<\/a><\/strong><\/p>\n

Media Contact<\/span>
Company Name:<\/strong> DelveInsight Business Research LLP<\/a>
Contact Person:<\/strong> Kritika Rehani
Email:<\/strong> Send Email<\/a>
Phone:<\/strong> +14699457679
Address:<\/strong>304 S. Jones Blvd #2432
City:<\/strong> Las Vegas
State:<\/strong> Nevada
Country:<\/strong> United States
Website:<\/strong> https:\/\/www.delveinsight.com\/<\/a><\/p>\n

<\/object>\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

Seborrhoeic Dermatitis Market The Seborrhoeic Dermatitis Market is anticipated to grow in the coming years owing to the potential launch of the pipeline therapiee, the rise in healthcare spending across the world, and the rise in the number of cases … Continue reading →<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,435,405,406,404],"tags":[],"class_list":["post-701656","post","type-post","status-publish","format-standard","hentry","category-Business","category-Europe","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/701656","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=701656"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/701656\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=701656"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=701656"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=701656"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}